LONDON, May 13 /PRNewswire/ -- Chiltern, a leading global research organization, announced that it has opened a new office in Lisbon, Portugal. Mr. Ricardo Diaz will head Chiltern's new office as Country Manager. Mr. Diaz has over 10 years experience in clinical research and holds a Master's Degree in Pharmacology, a Master's in Clinical trials and an MBA.
The office is staffed with highly qualified clinical research professionals, supporting Chiltern's on-going clinical studies in Portugal. Additionally, our Resourcing Solutions brand provides local sponsors with the opportunity to bring on board well-trained personnel, based at either clinical sites or the sponsors' offices, on short or long-term contracts.
"The conditions were right for us to open this new office. In the past 2 years, we have seen rising interest in the region and increased demand for full clinical operations support in Portugal," said Ricardo Diaz.
"Chiltern continues to invest in expanding our geographic footprint to support our sponsors' demands," commented Lewis Cameron, Executive Vice President Europe. "Quick patient enrollment and the small number of competitive trials add to the overall benefits of in running clinical studies in Portugal."
Established in 1982, Chiltern is a leading global Contract Research
Organization with extensive experience conducting and staffing
international Phase I to Phase IV clinical trials across a broad
therapeutic range for a wide variety of clients. Chiltern employs more than
1,200 people with 20 offices across the United States, Europe and in India.
Chiltern provides services including Early Phase, Global Clinical
Development, Late Phase, Biometrics, Medical and Regulatory Affairs and
For More Information Contact:
Catherine Lemercier Richard Baptista
Chiltern International, Inc. Chiltern International Ltd.
2111 Palomar Airport Road 171 Bath Road
Suite 200 Slough
CA 92011 SL1 4AA
USA UNITED KINGDOM
Tel: 1 (760) 707 5025 Tel: 44 (0) 1753 512 000
Fax: 1 (760) 707 5022 Fax: 44 (0) 1753 511 116
Copyright©2008 PR Newswire.
All rights reserved